{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T01:38:34Z","timestamp":1790213914768,"version":"4.1.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T00:00:00Z","timestamp":1696464000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T00:00:00Z","timestamp":1696464000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"E-Da Cancer Hospital","award":["EDCHP110015"],"award-info":[{"award-number":["EDCHP110015"]}]},{"name":"Ministry of Science and Technology","award":["MOST 111-2314-B-037-011-, MOST 111-2314-B-037-020-, MOST 111-2314-B-037-046"],"award-info":[{"award-number":["MOST 111-2314-B-037-011-, MOST 111-2314-B-037-020-, MOST 111-2314-B-037-046"]}]},{"name":"Ministry of Science and Technology","award":["MOST 111-2314-B-037-011-, MOST 111-2314-B-037-020-, MOST 111-2314-B-037-046"],"award-info":[{"award-number":["MOST 111-2314-B-037-011-, MOST 111-2314-B-037-020-, MOST 111-2314-B-037-046"]}]},{"name":"Kaohsiung Medical University Hospital","award":["KMUH110-0R43, KMUH-DK(A)110001"],"award-info":[{"award-number":["KMUH110-0R43, KMUH-DK(A)110001"]}]},{"name":"Kaohsiung Medical University Hospital","award":["KMUH110-0R43, KMUH-DK(A)110001"],"award-info":[{"award-number":["KMUH110-0R43, KMUH-DK(A)110001"]}]},{"DOI":"10.13039\/501100004694","name":"Kaohsiung Medical University","doi-asserted-by":"crossref","award":["KMU-DK(A)111005, NYCUKMU-111-I002"],"award-info":[{"award-number":["KMU-DK(A)111005, NYCUKMU-111-I002"]}],"id":[{"id":"10.13039\/501100004694","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004694","name":"Kaohsiung Medical University","doi-asserted-by":"crossref","award":["KMU-DK(A)111005, NYCUKMU-111-I002"],"award-info":[{"award-number":["KMU-DK(A)111005, NYCUKMU-111-I002"]}],"id":[{"id":"10.13039\/501100004694","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Cell Int"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>RAD51 overexpression has been reported to serve as a marker of poor prognosis in several cancer types. This study aimed to survey the role of RAD51 in oral squamous cell carcinoma and whether RAD51 could be a potential therapeutic target.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Materials and methods<\/jats:title>\n                <jats:p>RAD51 protein expression, assessed by immunohistochemical staining, was used to examine associations with survival and clinicopathological profiles of patients with oral squamous cell carcinoma. Lentiviral infection was used to knock down or overexpress RAD51. The influence of RAD51 on the biological profile of oral cancer cells was evaluated. Cell viability and apoptosis after treatment with chemotherapeutic agents and irradiation were analyzed. Co-treatment with chemotherapeutic agents and B02, a RAD51 inhibitor, was used to examine additional cytotoxic effects.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Oral squamous cell carcinoma patients with higher RAD51 expression exhibited worse survival, especially those treated with adjuvant chemotherapy and radiotherapy. RAD51 overexpression promotes resistance to chemotherapy and radiotherapy in oral cancer cells in vitro. Higher tumorsphere formation ability was observed in RAD51 overexpressing oral cancer cells. However, the expression of oral cancer stem cell markers did not change in immunoblotting analysis. Co-treatment with RAD51 inhibitor B02 and cisplatin, compared with cisplatin alone, significantly enhanced cytotoxicity in oral cancer cells.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>RAD51 is a poor prognostic marker for oral squamous cell carcinoma. High RAD51 protein expression associates with resistance to chemotherapy and radiotherapy. Addition of B02 significantly increased the cytotoxicity of cisplatin. These findings suggest that RAD51 protein may function as a treatment target for oral cancer.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>Number: KMUHIRB-E(I)-20190009 Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, approved on 20190130, Retrospective registration.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12935-023-03071-w","type":"journal-article","created":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T07:01:50Z","timestamp":1696489310000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["RAD51 is a poor prognostic marker and a potential therapeutic target for oral squamous cell carcinoma"],"prefix":"10.1186","volume":"23","author":[{"given":"Yu-Fen","family":"Tsai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leong-Perng","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuk-Kwan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Wei","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Wei","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Yun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shyng-Shiou F.","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,5]]},"reference":[{"issue":"3","key":"3071_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"3071_CR2","unstructured":"Lip oralcavity. (Globocan 2020 fact sheet). Lyon: International Agency for Research on Cancer; 2020 (https:\/\/gco.iarc.fr\/today\/data\/factsheets\/cancers\/1-Lip-oral-cavity-fact-sheet.pdf, accessed 06 December 2022)."},{"key":"3071_CR3","unstructured":"Ferlay JLM, Ervik M, Lam F, Colombet M, Mery L, Pi\u00f1eros M, Znaor A, Soerjomataram I, Bray F. Global Cancer Observatory: Cancer Tomorrow. Lyon, France: International Agency for Research on Cancer. 2020. https:\/\/gco.iarc.fr\/tomorrow. Accessed 06 December, 2022."},{"key":"3071_CR4","unstructured":"American Cancer Society. Cancer Facts & Fig.\u00a02023. Atlanta: American Cancer Society; 2023."},{"key":"3071_CR5","unstructured":"World Health Organization. (2022). Global oral health status report: towards universal health coverage for oral health by 2030. World Health Organization. https:\/\/apps.who.int\/iris\/handle\/10665\/364538"},{"key":"3071_CR6","unstructured":"Ministry of Health and, Welfare T, Cancer Registry Annual ROC. Report 2019. Accessed 06 December, 2022. https:\/\/www.hpa.gov.tw\/Pages\/ashx\/File.ashx?FilePath=~\/File\/Attach\/14913\/File_18302.pdf"},{"key":"3071_CR7","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.oraloncology.2015.01.001","volume":"51","author":"CC Huang","year":"2015","unstructured":"Huang CC, Ou CY, Lee WT, Hsiao JR, Tsai ST, Wang JD. Life expectancy and expected years of life lost to oral cancer in Taiwan: a nation-wide analysis of 22,024 cases followed for 10 years. Oral Oncol. 2015;51:349\u201354. https:\/\/doi.org\/10.1016\/j.oraloncology.2015.01.001","journal-title":"Oral Oncol"},{"key":"3071_CR8","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.molcel.2012.07.029","volume":"47","author":"JR Chapman","year":"2012","unstructured":"Chapman JR, Taylor MR, Boulton SJ. Playing the end game: DNA double-strand break repair pathway choice. Mol Cell. 2012;47:497\u2013510. https:\/\/doi.org\/10.1016\/j.molcel.2012.07.029","journal-title":"Mol Cell"},{"key":"3071_CR9","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.molcel.2010.09.019","volume":"40","author":"A Ciccia","year":"2010","unstructured":"Ciccia A, Elledge SJ. The DNA damage response: making it safe to play with knives. Mol Cell. 2010;40:179\u2013204. https:\/\/doi.org\/10.1016\/j.molcel.2010.09.019","journal-title":"Mol Cell"},{"key":"3071_CR10","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1111\/cas.12366","volume":"105","author":"N Hosoya","year":"2014","unstructured":"Hosoya N, Miyagawa K. Targeting DNA damage response in cancer therapy. Cancer Sci. 2014;105:370\u201388. https:\/\/doi.org\/10.1111\/cas.12366","journal-title":"Cancer Sci"},{"key":"3071_CR11","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.canlet.2004.08.009","volume":"218","author":"C Richardson","year":"2005","unstructured":"Richardson C. RAD51, genomic stability, and tumorigenesis. Cancer Lett. 2005;218:127\u201339. https:\/\/doi.org\/10.1016\/j.canlet.2004.08.009","journal-title":"Cancer Lett"},{"key":"3071_CR12","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1093\/jnci\/djs355","volume":"104","author":"SS Yuan","year":"2012","unstructured":"Yuan SS, Hou MF, Hsieh YC, et al. Role of MRE11 in cell proliferation, tumor invasion, and DNA repair in breast cancer. J Natl Cancer Inst. 2012;104:1485\u2013502. https:\/\/doi.org\/10.1093\/jnci\/djs355","journal-title":"J Natl Cancer Inst"},{"key":"3071_CR13","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1093\/nar\/gkp1063","volume":"38","author":"D Schild","year":"2010","unstructured":"Schild D, Wiese C. Overexpression of RAD51 suppresses recombination defects: a possible mechanism to reverse genomic instability. Nucleic Acids Res. 2010;38:1061\u201370. https:\/\/doi.org\/10.1093\/nar\/gkp1063","journal-title":"Nucleic Acids Res"},{"key":"3071_CR14","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1146\/annurev.biochem.77.061306.125255","volume":"77","author":"J San Filippo","year":"2008","unstructured":"San Filippo J, Sung P, Klein H. Mechanism of eukaryotic homologous recombination. Annu Rev Biochem. 2008;77:229\u201357. https:\/\/doi.org\/10.1146\/annurev.biochem.77.061306.125255","journal-title":"Annu Rev Biochem"},{"key":"3071_CR15","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s40169-016-0128-z","volume":"5","author":"S Bhattacharjee","year":"2016","unstructured":"Bhattacharjee S, Nandi S. Choices have consequences: the nexus between DNA repair pathways and genomic instability in cancer. Clin Transl Med. 2016;5:45\u20135. https:\/\/doi.org\/10.1186\/s40169-016-0128-z","journal-title":"Clin Transl Med"},{"key":"3071_CR16","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.molcel.2006.05.022","volume":"22","author":"B Xia","year":"2006","unstructured":"Xia B, Sheng Q, Nakanishi K, et al. Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol Cell. 2006;22:719\u201329. https:\/\/doi.org\/10.1016\/j.molcel.2006.05.022","journal-title":"Mol Cell"},{"key":"3071_CR17","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1038\/nsmb.1916","volume":"17","author":"E Dray","year":"2010","unstructured":"Dray E, Etchin J, Wiese C, et al. Enhancement of RAD51 recombinase activity by the tumor suppressor PALB2. Nat Struct Mol Biol. 2010;17:1255\u20139. https:\/\/doi.org\/10.1038\/nsmb.1916","journal-title":"Nat Struct Mol Biol"},{"key":"3071_CR18","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/nature09399","volume":"467","author":"RB Jensen","year":"2010","unstructured":"Jensen RB, Carreira A, Kowalczykowski SC. Purified human BRCA2 stimulates RAD51-mediated recombination. Nature. 2010;467:678\u201383. https:\/\/doi.org\/10.1038\/nature09399","journal-title":"Nature"},{"key":"3071_CR19","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.ccell.2019.09.004","volume":"36","author":"V Quereda","year":"2019","unstructured":"Quereda V, Bayle S, Vena F, et al. Therapeutic targeting of CDK12\/CDK13 in Triple-Negative breast Cancer. Cancer Cell. 2019;36:545\u2013558e547. https:\/\/doi.org\/10.1016\/j.ccell.2019.09.004","journal-title":"Cancer Cell"},{"key":"3071_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-019-0307-2","volume":"51","author":"EH Choi","year":"2019","unstructured":"Choi EH, Kim KP. E2F1 facilitates DNA break repair by localizing to break sites and enhancing the expression of homologous recombination factors. Exp Mol Med. 2019;51:1\u201312. https:\/\/doi.org\/10.1038\/s12276-019-0307-2","journal-title":"Exp Mol Med"},{"key":"3071_CR21","doi-asserted-by":"publisher","first-page":"e1008355","DOI":"10.1371\/journal.pgen.1008355","volume":"15","author":"EB Garcin","year":"2019","unstructured":"Garcin EB, Gon S, Sullivan MR, et al. Differential requirements for the RAD51 paralogs in genome repair and maintenance in human cells. PLoS Genet. 2019;15:e1008355. https:\/\/doi.org\/10.1371\/journal.pgen.1008355","journal-title":"PLoS Genet"},{"key":"3071_CR22","doi-asserted-by":"publisher","unstructured":"Orhan E, Velazquez C, Tabet I, Sardet C, Theillet C. Regulation of RAD51 at the Transcriptional and Functional Levels: What Prospects for Cancer Therapy? Cancers (Basel). 2021; 13. https:\/\/doi.org\/10.3390\/cancers13122930","DOI":"10.3390\/cancers13122930"},{"key":"3071_CR23","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1111\/jop.12903","volume":"48","author":"O Kujan","year":"2019","unstructured":"Kujan O, Huang G, Ravindran A, Vijayan M, Farah CS. The role of cyclin-dependent kinases in oral potentially malignant disorders and oral squamous cell carcinoma. J Oral Pathol Med. 2019;48:560\u20135. https:\/\/doi.org\/10.1111\/jop.12903","journal-title":"J Oral Pathol Med"},{"key":"3071_CR24","doi-asserted-by":"publisher","unstructured":"Shrivastava N, Chavez CG, Li D, et al. CDK4\/6 inhibition induces senescence and enhances Radiation Response by disabling DNA damage repair in oral cavity squamous cell carcinoma. Cancers (Basel). 2023;15. https:\/\/doi.org\/10.3390\/cancers15072005","DOI":"10.3390\/cancers15072005"},{"key":"3071_CR25","first-page":"219","volume":"62","author":"E Raderschall","year":"2002","unstructured":"Raderschall E, Stout K, Freier S, Suckow V, Schweiger S, Haaf T. Elevated levels of Rad51 recombination protein in tumor cells. Cancer Res. 2002;62:219\u201325.","journal-title":"Cancer Res"},{"key":"3071_CR26","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.dnarep.2007.12.008","volume":"7","author":"HL Klein","year":"2008","unstructured":"Klein HL. The consequences of Rad51 overexpression for normal and tumor cells. DNA Repair (Amst). 2008;7:686\u201393. https:\/\/doi.org\/10.1016\/j.dnarep.2007.12.008","journal-title":"DNA Repair (Amst)"},{"key":"3071_CR27","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1002\/1097-0215(20001215)88:6<907::aid-ijc11>3.0.co;2-4","volume":"88","author":"H Maacke","year":"2000","unstructured":"Maacke H, Opitz S, Jost K, et al. Over-expression of wild-type Rad51 correlates with histological grading of invasive ductal breast cancer. Int J Cancer. 2000;88:907\u201313. https:\/\/doi.org\/10.1002\/1097-0215(20001215)88:6%3C;907::aid-ijc11%3E;3.0.co;2-4","journal-title":"Int J Cancer"},{"key":"3071_CR28","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.1038\/sj.onc.1203578","volume":"19","author":"H Maacke","year":"2000","unstructured":"Maacke H, Jost K, Opitz S, et al. DNA repair and recombination factor Rad51 is over-expressed in human pancreatic adenocarcinoma. Oncogene. 2000;19:2791\u20135. https:\/\/doi.org\/10.1038\/sj.onc.1203578","journal-title":"Oncogene"},{"key":"3071_CR29","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1111\/j.1365-2559.2009.03448.x","volume":"55","author":"A Mitra","year":"2009","unstructured":"Mitra A, Jameson C, Barbachano Y, et al. Overexpression of RAD51 occurs in aggressive prostatic cancer. Histopathology. 2009;55:696\u2013704. https:\/\/doi.org\/10.1111\/j.1365-2559.2009.03448.x","journal-title":"Histopathology"},{"key":"3071_CR30","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1002\/ijc.22738","volume":"121","author":"T Takenaka","year":"2007","unstructured":"Takenaka T, Yoshino I, Kouso H, et al. Combined evaluation of Rad51 and ERCC1 expressions for sensitivity to platinum agents in non-small cell lung cancer. Int J Cancer. 2007;121:895\u2013900. https:\/\/doi.org\/10.1002\/ijc.22738","journal-title":"Int J Cancer"},{"key":"3071_CR31","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1245\/s10434-013-3220-2","volume":"21","author":"T Nakanoko","year":"2014","unstructured":"Nakanoko T, Saeki H, Morita M, et al. Rad51 expression is a useful predictive factor for the efficacy of neoadjuvant chemoradiotherapy in squamous cell carcinoma of the esophagus. Ann Surg Oncol. 2014;21:597\u2013604. https:\/\/doi.org\/10.1245\/s10434-013-3220-2","journal-title":"Ann Surg Oncol"},{"key":"3071_CR32","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1002\/jso.22018","volume":"104","author":"Y Li","year":"2011","unstructured":"Li Y, Yu H, Luo RZ, et al. Elevated expression of Rad51 is correlated with decreased survival in resectable esophageal squamous cell carcinoma. J Surg Oncol. 2011;104:617\u201322. https:\/\/doi.org\/10.1002\/jso.22018","journal-title":"J Surg Oncol"},{"key":"3071_CR33","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.bcp.2011.12.022","volume":"83","author":"Z Yang","year":"2012","unstructured":"Yang Z, Waldman AS, Wyatt MD. Expression and regulation of RAD51 mediate cellular responses to chemotherapeutics. Biochem Pharmacol. 2012;83:741\u20136. https:\/\/doi.org\/10.1016\/j.bcp.2011.12.022","journal-title":"Biochem Pharmacol"},{"key":"3071_CR34","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1002\/ijc.11106","volume":"105","author":"LT Hansen","year":"2003","unstructured":"Hansen LT, Lundin C, Spang-Thomsen M, Petersen LN, Helleday T. The role of RAD51 in etoposide (VP16) resistance in small cell lung cancer. Int J Cancer. 2003;105:472\u20139.","journal-title":"Int J Cancer"},{"key":"3071_CR35","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1007\/s12032-010-9605-1","volume":"28","author":"LQ Du","year":"2011","unstructured":"Du LQ, Wang Y, Wang H, Cao J, Liu Q, Fan FY. Knockdown of Rad51 expression induces radiation- and chemo-sensitivity in osteosarcoma cells. Med Oncol. 2011;28:1481\u20137.","journal-title":"Med Oncol"},{"key":"3071_CR36","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1124\/jpet.110.173146","volume":"335","author":"MS Tsai","year":"2010","unstructured":"Tsai MS, Kuo YH, Chiu YF, Su YC, Lin YW. Down-regulation of Rad51 expression overcomes drug resistance to gemcitabine in human non-small-cell lung cancer cells. J Pharmacol Exp Ther. 2010;335:830\u201340. https:\/\/doi.org\/10.1124\/jpet.110.173146","journal-title":"J Pharmacol Exp Ther"},{"key":"3071_CR37","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1186\/s12935-021-01953-5","volume":"21","author":"Y Feng","year":"2021","unstructured":"Feng Y, Wang D, Xiong L, Zhen G, Tan J. Predictive value of RAD51 on the survival and drug responsiveness of ovarian cancer. Cancer Cell Int. 2021;21:249. https:\/\/doi.org\/10.1186\/s12935-021-01953-5","journal-title":"Cancer Cell Int"},{"key":"3071_CR38","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1002\/cam4.1505","volume":"7","author":"A Pataer","year":"2018","unstructured":"Pataer A, Shao R, Correa AM, et al. Major pathologic response and RAD51 predict survival in lung cancer patients receiving neoadjuvant chemotherapy. Cancer Med. 2018;7:2405\u201314. https:\/\/doi.org\/10.1002\/cam4.1505","journal-title":"Cancer Med"},{"key":"3071_CR39","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/sj.bjc.6602665","volume":"93","author":"GB Qiao","year":"2005","unstructured":"Qiao GB, Wu YL, Yang XN, et al. High-level expression of Rad51 is an independent prognostic marker of survival in non-small-cell lung cancer patients. Br J Cancer. 2005;93:137\u201343. https:\/\/doi.org\/10.1038\/sj.bjc.6602665","journal-title":"Br J Cancer"},{"key":"3071_CR40","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.bbcan.2011.07.004","volume":"1816","author":"NS Nagathihalli","year":"2011","unstructured":"Nagathihalli NS, Nagaraju G. RAD51 as a potential biomarker and therapeutic target for pancreatic cancer. Biochim Biophys Acta. 2011;1816:209\u201318. https:\/\/doi.org\/10.1016\/j.bbcan.2011.07.004","journal-title":"Biochim Biophys Acta"},{"key":"3071_CR41","first-page":"5788","volume":"11","author":"Y Xu","year":"2019","unstructured":"Xu Y, Chen K, Cai Y, Cheng C, Zhang Z, Xu G. Overexpression of Rad51 predicts poor prognosis and silencing of Rad51 increases chemo-sensitivity to doxorubicin in neuroblastoma. Am J Transl Res. 2019;11:5788\u201399.","journal-title":"Am J Transl Res"},{"key":"3071_CR42","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s10549-022-06552-0","volume":"193","author":"R Wu","year":"2022","unstructured":"Wu R, Patel A, Tokumaru Y, et al. High RAD51 gene expression is associated with aggressive biology and with poor survival in breast cancer. Breast Cancer Res Treat. 2022;193:49\u201363. https:\/\/doi.org\/10.1007\/s10549-022-06552-0","journal-title":"Breast Cancer Res Treat"},{"key":"3071_CR43","doi-asserted-by":"publisher","unstructured":"Li Y, Li J, Sun J et al. Expression of RAD51 and Its Clinical Impact in Oral Squamous Cell Carcinoma. Anal Cell Pathol (Amst). 2020; 2020: 1827676. https:\/\/doi.org\/10.1155\/2020\/1827676","DOI":"10.1155\/2020\/1827676"},{"key":"3071_CR44","unstructured":"Amin MB, Greene ES, F.L., et al. editors. AJCC Cancer Staging Manual. 8th edition. Springer, New York, NY 2017."},{"key":"3071_CR45","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1093\/jnci\/djs355","volume":"104","author":"S-SF Yuan","year":"2012","unstructured":"Yuan S-SF, Hou M-F, Hsieh Y-C, et al. Role of MRE11 in cell proliferation, Tumor Invasion, and DNA repair in breast Cancer. JNCI: J Natl Cancer Inst. 2012;104:1485\u2013502. https:\/\/doi.org\/10.1093\/jnci\/djs355","journal-title":"JNCI: J Natl Cancer Inst"},{"key":"3071_CR46","doi-asserted-by":"publisher","first-page":"3510","DOI":"10.1038\/s41388-021-01698-5","volume":"40","author":"YY Wang","year":"2021","unstructured":"Wang YY, Chen YK, Lo S, et al. MRE11 promotes oral cancer progression through RUNX2\/CXCR4\/AKT\/FOXA2 signaling in a nuclease-independent manner. Oncogene. 2021;40:3510\u201332. https:\/\/doi.org\/10.1038\/s41388-021-01698-5","journal-title":"Oncogene"},{"key":"3071_CR47","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/1759-7714.12274","volume":"7","author":"X Zhong","year":"2016","unstructured":"Zhong X, Luo G, Zhou X, et al. Rad51 in regulating the radiosensitivity of non-small cell lung cancer with different epidermal growth factor receptor mutation status. Thorac Cancer. 2016;7:50\u201360. https:\/\/doi.org\/10.1111\/1759-7714.12274","journal-title":"Thorac Cancer"},{"key":"3071_CR48","doi-asserted-by":"publisher","first-page":"e23427","DOI":"10.1371\/journal.pone.0023427","volume":"6","author":"Q Liu","year":"2011","unstructured":"Liu Q, Jiang H, Liu Z, et al. Berberine radiosensitizes human esophageal cancer cells by downregulating homologous recombination repair protein RAD51. PLoS ONE. 2011;6:e23427. https:\/\/doi.org\/10.1371\/journal.pone.0023427","journal-title":"PLoS ONE"},{"key":"3071_CR49","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1093\/carcin\/bgs340","volume":"34","author":"N Kotova","year":"2013","unstructured":"Kotova N, Vare D, Schultz N, et al. Genotoxicity of alcohol is linked to DNA replication-associated damage and homologous recombination repair. Carcinogenesis. 2013;34:325\u201330. https:\/\/doi.org\/10.1093\/carcin\/bgs340","journal-title":"Carcinogenesis"},{"key":"3071_CR50","doi-asserted-by":"publisher","first-page":"zcaa024","DOI":"10.1093\/narcan\/zcaa024","volume":"2","author":"MK Grundy","year":"2020","unstructured":"Grundy MK, Buckanovich RJ, Bernstein KA. Regulation and pharmacological targeting of RAD51 in cancer. NAR Cancer. 2020;2:zcaa024. https:\/\/doi.org\/10.1093\/narcan\/zcaa024","journal-title":"NAR Cancer"},{"key":"3071_CR51","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1021\/cb100428c","volume":"6","author":"F Huang","year":"2011","unstructured":"Huang F, Motlekar NA, Burgwin CM, Napper AD, Diamond SL, Mazin AV. Identification of specific inhibitors of human RAD51 recombinase using high-throughput screening. ACS Chem Biol. 2011;6:628\u201335. https:\/\/doi.org\/10.1021\/cb100428c","journal-title":"ACS Chem Biol"},{"key":"3071_CR52","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.1021\/jm201173g","volume":"55","author":"F Huang","year":"2012","unstructured":"Huang F, Mazina OM, Zentner IJ, Cocklin S, Mazin AV. Inhibition of homologous recombination in human cells by targeting RAD51 recombinase. J Med Chem. 2012;55:3011\u201320. https:\/\/doi.org\/10.1021\/jm201173g","journal-title":"J Med Chem"},{"key":"3071_CR53","doi-asserted-by":"publisher","first-page":"289","DOI":"10.3389\/fonc.2014.00289","volume":"4","author":"DA Alagpulinsa","year":"2014","unstructured":"Alagpulinsa DA, Ayyadevara S, Shmookler Reis RJ. A small-molecule inhibitor of RAD51 reduces homologous recombination and sensitizes multiple myeloma cells to Doxorubicin. Front Oncol. 2014;4:289. https:\/\/doi.org\/10.3389\/fonc.2014.00289","journal-title":"Front Oncol"},{"key":"3071_CR54","doi-asserted-by":"publisher","first-page":"e100993","DOI":"10.1371\/journal.pone.0100993","volume":"9","author":"F Huang","year":"2014","unstructured":"Huang F, Mazin AV. A small molecule inhibitor of human RAD51 potentiates breast cancer cell killing by therapeutic agents in mouse xenografts. PLoS ONE. 2014;9:e100993. https:\/\/doi.org\/10.1371\/journal.pone.0100993","journal-title":"PLoS ONE"},{"key":"3071_CR55","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1200\/JCO.2021.39.15_suppl.3006","volume":"39","author":"RC Lynch","year":"2021","unstructured":"Lynch RC, Bendell JC, Advani RH, et al. First-in-human phase I\/II study of CYT-0851, a first-in-class inhibitor of RAD51-mediated homologous recombination in patients with advanced solid and hematologic cancers. J Clin Oncol. 2021;39:3006\u20136.","journal-title":"J Clin Oncol"},{"key":"3071_CR56","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1245\/s10434-019-08043-x","volume":"27","author":"WC Chiu","year":"2020","unstructured":"Chiu WC, Fang PT, Lee YC, et al. DNA repair protein Rad51 induces Tumor Growth and Metastasis in Esophageal squamous cell Carcinoma via a p38\/Akt-Dependent pathway. Ann Surg Oncol. 2020;27:2090\u2013101. https:\/\/doi.org\/10.1245\/s10434-019-08043-x","journal-title":"Ann Surg Oncol"},{"key":"3071_CR57","doi-asserted-by":"publisher","first-page":"767","DOI":"10.3892\/or.2017.5724","volume":"38","author":"Q Chen","year":"2017","unstructured":"Chen Q, Cai D, Li M, Wu X. The homologous recombination protein RAD51 is a promising therapeutic target for cervical carcinoma. Oncol Rep. 2017;38:767\u201374. https:\/\/doi.org\/10.3892\/or.2017.5724","journal-title":"Oncol Rep"}],"container-title":["Cancer Cell International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-023-03071-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12935-023-03071-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-023-03071-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T16:25:23Z","timestamp":1700411123000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancerci.biomedcentral.com\/articles\/10.1186\/s12935-023-03071-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,5]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3071"],"URL":"https:\/\/doi.org\/10.1186\/s12935-023-03071-w","relation":{},"ISSN":["1475-2867"],"issn-type":[{"value":"1475-2867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,5]]},"assertion":[{"value":"25 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Institutional Review Board of Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, in 2019 (KMUHIRB-E(I)-20190009).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"231"}}